Literature DB >> 33272154

Liver Transplant for Management of Hepatic Complications of Dyskeratosis Congenita: A Case Report.

Musab Alebrahim1, Clifford Akateh, Christina A Arnold, Dathe Benissan-Messan, Jesus A Chavez, Navdeep Singh, Yazan Al-Adwan, Ashraf El-Hinnawi, Anthony Michaels, Sylvester M Black.   

Abstract

Dyskeratosis congenita, a rare genetic disorder typified by progressive bone marrow failure, is classically characterized by the triad of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia; however, it is a multisystem disease. Although hepatic involvement occurs in about 7% of patients with dyskeratosis congenita, end-stage liver disease is rare. Treatment of dyskeratosis congenita generally involves hematopoietic stem cell transplant. For patients with hepatic failure, liver transplant can be an option. Here, we describe a case of a patient with dyskeratosis congenita who presented with liver failure and pulmonary failure, precluding him from hematopoietic stem cell transplant. After liver transplant, the patient had significant improvements in pulmonary function and transfusion requirements, allowing the patient to qualify for hematopoietic stem cell transplant. Although hematopoietic stem cell transplant is typically the first step in the management of dyskeratosis congenita, for patients with severe hepatic manifestations of the disease, a liver transplant first approach may result in better disease management.

Entities:  

Mesh:

Year:  2020        PMID: 33272154      PMCID: PMC8155112          DOI: 10.6002/ect.2020.0073

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.938


  13 in total

Review 1.  Dyskeratosis congenita.

Authors:  Inderjeet Dokal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders.

Authors:  Amany I Gorgy; Naudia L Jonassaint; Susan E Stanley; Ayman Koteish; Amy E DeZern; Jolan E Walter; Sabrina C Sopha; James P Hamilton; Julie Hoover-Fong; Allen R Chen; Robert A Anders; Ihab R Kamel; Mary Armanios
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

3.  The gastrointestinal manifestations of telomere-mediated disease.

Authors:  Naudia L Jonassaint; Nini Guo; Joseph A Califano; Elizabeth A Montgomery; Mary Armanios
Journal:  Aging Cell       Date:  2013-01-04       Impact factor: 9.304

4.  X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions.

Authors:  N S Heiss; S W Knight; T J Vulliamy; S M Klauck; S Wiemann; P J Mason; A Poustka; I Dokal
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

Review 5.  Dyskeratosis congenita as a disorder of telomere maintenance.

Authors:  Nya D Nelson; Alison A Bertuch
Journal:  Mutat Res       Date:  2011-07-02       Impact factor: 2.433

Review 6.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

7.  Telomerase gene mutations are associated with cirrhosis formation.

Authors:  Daniel Hartmann; Ujala Srivastava; Michaela Thaler; Karin N Kleinhans; Gisèle N'kontchou; Annika Scheffold; Kerstin Bauer; Ramona F Kratzer; Natalia Kloos; Sarah-Fee Katz; Zhangfa Song; Yvonne Begus-Nahrmann; Alexander Kleger; Guido von Figura; Pavel Strnad; André Lechel; Cagatay Günes; Andrej Potthoff; Katja Deterding; Heiner Wedemeyer; Zhenyu Ju; Ge Song; Feng Xiao; Sonja Gillen; Hubert Schrezenmeier; Thomas Mertens; Marianne Ziol; Helmut Friess; Michael Jarek; Michael P Manns; Michel Beaugrand; K Lenhard Rudolph
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

8.  Unusual complications after bone marrow transplantation for dyskeratosis congenita.

Authors:  V Rocha; A Devergie; G Socié; P Ribaud; H Espérou; N Parquet; E Gluckman
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

9.  Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis.

Authors:  Luca Valenti; Paola Dongiovanni; Marco Maggioni; Benedetta Maria Motta; Raffaela Rametta; Marta Milano; Silvia Fargion; Paolo Reggiani; Anna Ludovica Fracanzani
Journal:  J Hepatol       Date:  2012-09-19       Impact factor: 25.083

10.  A spectrum of severe familial liver disorders associate with telomerase mutations.

Authors:  Rodrigo T Calado; Joshua A Regal; David E Kleiner; David S Schrump; Nathan R Peterson; Veronica Pons; Stephen J Chanock; Peter M Lansdorp; Neal S Young
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.